Further follow up of the UKCTOCS population screening trial is expected after planned censorship in 2018 and 2024, with reporting in 2020. It is also possible that additional post hoc analyses (including outcomes by tumour type) may be reported. No other clinical trials of population screening for ovarian cancer in asymptomatic women are currently ongoing.
A number of tests for ovarian cancer diagnosis or prognosis are under investigation; however, their potential for application as a screening tool is not yet known. DNA, plasma, serum and tissue samples from the large screening trials are being used to investigate new biomarkers, tests, and prediction models that may improve upon the ROCA algorithm. The use of any new detection tools or strategies would require further validation and testing to assess the potential clinical benefits for ovarian cancer screening or surveillance.
As there are currently no clinical trials of population screening for ovarian cancer in asymptomatic women, no new technologies are likely to be introduced or recommended for screening or surveillance in the short- to medium-term. In light of the emerging understanding of the heterogeneity of ovarian cancers and early disease development, it is highly unlikely that a single biomarker or imaging modality will be sufficient to detect each of the various subtypes at their earliest stages.